Free Trial

This company has been marked as potentially delisted and may not be actively trading.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. FEMY, CARA, TENX, LSTA, CCM, CYTH, FBLG, KLTO, GBS, and CRIS

Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Femasys (FEMY), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Concord Medical Services (CCM), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), GBS (GBS), and Curis (CRIS). These companies are all part of the "medical" sector.

XTL Biopharmaceuticals vs. Its Competitors

XTL Biopharmaceuticals (NASDAQ:XTLB) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. XTL Biopharmaceuticals' return on equity of 0.00% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
XTL BiopharmaceuticalsN/A N/A N/A
Femasys -1,242.06%-392.45%-137.15%

In the previous week, Femasys had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Femasys and 1 mentions for XTL Biopharmaceuticals. Femasys' average media sentiment score of 0.92 beat XTL Biopharmaceuticals' score of 0.00 indicating that Femasys is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XTL Biopharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Femasys
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 11.5% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Femasys has a consensus price target of $8.67, indicating a potential upside of 832.60%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Femasys
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

XTL Biopharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, meaning that its share price is 356% less volatile than the S&P 500.

XTL Biopharmaceuticals has higher earnings, but lower revenue than Femasys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL Biopharmaceuticals$450K16.17-$1.03MN/AN/A
Femasys$1.70M13.97-$18.82M-$0.91-1.02

Summary

XTL Biopharmaceuticals and Femasys tied by winning 7 of the 14 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XTLB vs. The Competition

MetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.19M$415.98M$5.52B$9.02B
Dividend YieldN/A2.45%5.24%4.05%
P/E RatioN/A7.2127.2520.08
Price / Sales16.173.36371.3293.25
Price / CashN/A8.4126.2128.59
Price / Book1.340.897.945.55
Net Income-$1.03M$10.55M$3.17B$248.49M

XTL Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XTLB
XTL Biopharmaceuticals
0.2 of 5 stars
$1.34
+18.1%
N/AN/A$7.19M$450K0.00N/ANews Coverage
FEMY
Femasys
3.8107 of 5 stars
$0.97
-1.4%
$8.67
+797.4%
-16.3%$25.04M$1.63M-1.0630
CARA
Cara Therapeutics
0.34 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.2376 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+81.4%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4621 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-29.3%$24.12M$1M-1.2630Positive News
CCM
Concord Medical Services
0.8418 of 5 stars
$5.73
+4.0%
N/A-46.2%$23.92M$52.60M0.00970News Coverage
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
FBLG
FibroBiologics
2.5355 of 5 stars
$0.62
+0.7%
$13.00
+1,989.4%
-87.7%$23.65MN/A-2.9610News Coverage
Gap Up
KLTO
Klotho Neurosciences
N/A$1.13
+56.9%
N/AN/A$23.40MN/A-3.14N/AAnalyst Upgrade
Gap Down
High Trading Volume
GBS
GBS
N/A$1.53
-9.5%
N/A-2.7%$22.78M$440K-2.737News Coverage
CRIS
Curis
2.8845 of 5 stars
$2.32
+6.9%
$17.00
+632.8%
-72.7%$22.70M$10.91M-0.3760High Trading Volume

Related Companies and Tools


This page (NASDAQ:XTLB) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners